Joffre Olivier, Santolaria Thibault, Calise Denis, Al Saati Talal, Hudrisier Denis, Romagnoli Paola, van Meerwijk Joost P M
Institut National de la Santé et de la Recherche Médicale, U563, Tolerance and Autoimmunity section, Toulouse, F-31300 France.
Nat Med. 2008 Jan;14(1):88-92. doi: 10.1038/nm1688. Epub 2007 Dec 9.
A major challenge in transplantation medicine is controlling the very strong immune responses to foreign antigens that are responsible for graft rejection. Although immunosuppressive drugs efficiently inhibit acute graft rejection, a substantial proportion of patients suffer chronic rejection that ultimately leads to functional loss of the graft. Induction of immunological tolerance to transplants would avoid rejection and the need for lifelong treatment with immunosuppressive drugs. Tolerance to self-antigens is ensured naturally by several mechanisms; one major mechanism depends on the activity of regulatory T lymphocytes. Here we show that in mice treated with clinically acceptable levels of irradiation, regulatory CD4+CD25+Foxp3+ T cells stimulated in vitro with alloantigens induced long-term tolerance to bone marrow and subsequent skin and cardiac allografts. Regulatory T cells specific for directly presented donor antigens prevented only acute rejection, despite hematopoietic chimerism. By contrast, regulatory T cells specific for both directly and indirectly presented alloantigens prevented both acute and chronic rejection. Our findings demonstrate the potential of appropriately stimulated regulatory T cells for future cell-based therapeutic approaches to induce lifelong immunological tolerance to allogeneic transplants.
移植医学中的一个主要挑战是控制对导致移植排斥的外来抗原的强烈免疫反应。尽管免疫抑制药物能有效抑制急性移植排斥,但仍有相当一部分患者会遭受慢性排斥,最终导致移植器官功能丧失。诱导对移植的免疫耐受将避免排斥反应以及终身使用免疫抑制药物治疗的必要性。对自身抗原的耐受通过多种机制自然得以确保;一种主要机制依赖于调节性T淋巴细胞的活性。我们在此表明,在用临床可接受剂量的辐射处理的小鼠中,体外经同种异体抗原刺激的调节性CD4 + CD25 + Foxp3 + T细胞可诱导对骨髓以及随后的皮肤和心脏同种异体移植的长期耐受。尽管存在造血嵌合体,但针对直接呈递的供体抗原的调节性T细胞仅能预防急性排斥。相比之下,针对直接和间接呈递的同种异体抗原的调节性T细胞既能预防急性排斥,也能预防慢性排斥。我们的研究结果证明了适当刺激的调节性T细胞在未来基于细胞的治疗方法中诱导对同种异体移植的终身免疫耐受的潜力。